Foghorn Therapeutics Names Ryan Maynard As Chief Financial Officer To Strengthen Financial Strategy

Foghorn Therapeutics Inc. announced the appointment of Ryan Maynard as Chief Financial Officer, effective February 23, 2026. Maynard brings more than 25 years of executive leadership experience in financial strategy, capital markets, and operational execution across both public and private biopharmaceutical companies. He will oversee Foghorn’s financial operations as the company advances its clinical-stage pipeline focused on correcting abnormal gene expression.

Most recently, Maynard served as CFO at Cara Therapeutics, Inc., where he led financial strategy and key strategic transactions. During his tenure, he executed a reverse merger with Tvardi Therapeutics, secured $37.5 million through a non-dilutive royalty financing, and supported commercial manufacturing and launch planning for KORSUVA®.

“I am delighted to welcome Ryan to Foghorn as our new CFO as we continue to advance our first-in-class pipeline," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. “Ryan is a seasoned biotech executive who brings proven financial and operational leadership. His experience scaling organisations will accelerate our mission to deliver novel therapies to patients.”

Earlier in his career, Maynard held CFO roles at Rigel Pharmaceuticals, LetsGetChecked Inc., and Blade Therapeutics. At Rigel, he played a key role in the FDA approval and commercial launch preparation of TAVALISSE® and raised more than $1 billion through public and private financings. He has developed strong relationships with healthcare-focused investors throughout his career.

Ryan Maynard, Chief Financial Officer of Foghorn, added, “I am excited to join Foghorn at this pivotal time as the Company’s lead program advances in dose escalation in partnership with Lilly, and our selective degrader portfolio nears the clinic. I look forward to partnering with the executive team and Board to provide disciplined financial leadership, drive execution, and support long-term growth and value creation.”

Maynard holds a Bachelor of Science in Commerce with a concentration in accounting from Santa Clara University. He also currently serves on the board of Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company.